Posted on 01/02/2010 in Pharmaceutical Company Financials Lilly has posted its financial results for 2009, revealing a strong performance for the period, according to the company's chairman and chief executive officer.
The firm's total revenue reached $5,934 million (3,723 million pounds) during the final quarter of the year, as opposed to $5,204.4 million during the same time in 2008.
This represents growth of 14 per cent, as eight products each exceeded sales of $1 billion for the whole of 2009.
John Lechleiter, chairman and chief executive officer of Lilly, explained that the company's results leave it "well-positioned" to approach 2010.
"In 2009, we delivered solid financial results even as we continued to implement a series of actions aimed at speeding innovation to patients and delivering greater value to our customers," he added.
Earlier this month, Mr Lechleiter emphasised the benefits that medical breakthroughs have for mankind and stated that Lilly's goals within the next decade include focusing upon innovative research and development. Other news stories from 01/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
